治疗环境的变化与晚期肝细胞癌的存活率改善有关:全国性的基于人口的研究
Najib Ben Khaled1, Bernhard Mörtl2, Dominik Beier3
1Department of Medicine II, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Institute of Molecular Oncology and Functional Genomics, School of Medicine, TU München, Munich, Germany.
对肝细胞癌 (HCC) 的新系统疗法适度改善了生存率,但增加了医疗保健成本. 这项现实研究分析了这些治疗方法在西方队列中的生存率和成本影响.
科学领域:
- 肝细胞癌 (HCC) 研究研究
- 瘤学 治疗学 治疗学
- 卫生经济学 卫生经济学
背景情况:
- 肝细胞癌 (HCC) 治疗正在随着新的全身疗法而发展.
- 本研究研究了这些变化对生存和成本的现实影响.
研究的目的:
- 分析与HCC新系统疗法相关的生存结果和医疗费用.
- 为了比较伦瓦提尼布和其他药物的批准前和之后的治疗时期.
主要方法:
- 使用全国索赔数据库 (InGef) 针对2015-2020年HCC病例.
- 两个时期的生存和医疗费用比较:仅索拉芬尼布时代和伦瓦替尼布批准后的时代.
- 评估了随着时间的推移对全身治疗利用率的变化.
主要成果:
- 鉴定了2876名HCC患者;全身治疗使用率从11.8% (2015) 增加到15.1% (2020).
- 平均整体存活时间从5.3个月 (A期) 提高到6.5个月 (B期;p=0.046).
- 伦瓦提尼布的生存时间 (9.7个月) 与索拉费尼布 (4.8个月;p=0.008) 相比有所改善,药物和门诊费用增加.
结论:
- 新的全身疗法为HCC患者提供了生存益处.
- 生存率的增长很小,并伴随着医疗保健支出的适度增加.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
